Pipeline
OKYO is focused on developing innovative GPCR-based therapies for eye diseases with significant unmet needs with a market with substantial growth potential. Specifically, the company is advancing first-in-class drug candidates aimed at treating ocular pain, dry eye disease, and uveitis. OKYO’s lead drug candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic.
A Focus on Ocular Therapies
Pipeline
Urcosimod (Formally OK-101)
Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
Neuropathic Corneal Pain (NCP)
Phase 2 Trial Initiated Q3 2024
Dry Eye Disease (DED)
Phase 2 Trial Completed Q4 2023
Allergic Conjunctivitis
Uveitis
OK-201
Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
Discovery Program
Urcosimod (formally OK-101) Development Timeline

